TILS18 Feb 2021 10:13
From the last RNS and taking place now;
Dr. Kunwar Shailubhai, CEO and CSO of Tiziana Life Sciences, commented, "I look forward to sharing our exciting story with conference attendees. With the release of our topline data from our COVID-19 trial, multiple Phase 2 trial launches expected in 2021, and the potential application of Foralumab in a wide range of autoimmune and inflammatory diseases in the longer-term, we are well positioned to achieve a series of important milestones in the months and quarters ahead."
Maybe get another of the doctors update presentations next week as he seems to like to do them around the same time as conferences.